-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $151.00
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $151.00
Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) have received a consensus rating of "Hold" from the nine research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $128.25.
A number of research firms have recently commented on NVAX. JPMorgan Chase & Co. lowered shares of Novavax from a "neutral" rating to an "underweight" rating and cut their price objective for the company from $132.00 to $27.00 in a research report on Thursday. Cowen reduced their target price on Novavax to $110.00 in a research note on Monday, August 15th. B. Riley reduced their target price on Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. Cowen reduced their target price on Novavax from $150.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 9th. Finally, Cantor Fitzgerald increased their target price on Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th.
Get Novavax alerts:Novavax Stock Performance
NVAX opened at $21.00 on Thursday. The firm has a market cap of $1.64 billion, a P/E ratio of -1.08, a PEG ratio of 0.10 and a beta of 1.65. The firm has a 50-day moving average of $41.22 and a 200 day moving average of $52.06. Novavax has a fifty-two week low of $20.46 and a fifty-two week high of $257.30.
Novavax (NASDAQ:NVAX – Get Rating) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing analysts' consensus estimates of $5.51 by ($12.04). The business had revenue of $186.00 million for the quarter, compared to the consensus estimate of $1.02 billion. Novavax had a negative return on equity of 572.54% and a negative net margin of 114.32%. Novavax's revenue for the quarter was down 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($4.75) EPS. Equities research analysts predict that Novavax will post 6.09 earnings per share for the current fiscal year.Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of NVAX. Mascoma Wealth Management LLC purchased a new position in Novavax during the 2nd quarter valued at approximately $27,000. San Luis Wealth Advisors LLC purchased a new position in Novavax during the 1st quarter worth approximately $29,000. Focused Wealth Management Inc purchased a new position in shares of Novavax during the 1st quarter valued at approximately $45,000. Exchange Traded Concepts LLC purchased a new position in shares of Novavax during the 2nd quarter valued at approximately $47,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Novavax in the 1st quarter worth $53,000. Institutional investors own 42.63% of the company's stock.
Novavax Company Profile
(Get Rating)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Featured Stories
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) have received a consensus rating of "Hold" from the nine research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $128.25.
據Marketbeat報道,諾華公司(納斯達克代碼:NVAX-GET Rating)的股票得到了九家研究公司的一致評級,即持有。兩名分析師對該股的評級為賣出建議,一名分析師給出了持有建議,三名分析師給出了買入建議。過去一年對該股進行評級的分析師的平均12個月目標價為128.25美元。
A number of research firms have recently commented on NVAX. JPMorgan Chase & Co. lowered shares of Novavax from a "neutral" rating to an "underweight" rating and cut their price objective for the company from $132.00 to $27.00 in a research report on Thursday. Cowen reduced their target price on Novavax to $110.00 in a research note on Monday, August 15th. B. Riley reduced their target price on Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. Cowen reduced their target price on Novavax from $150.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 9th. Finally, Cantor Fitzgerald increased their target price on Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th.
一些研究公司最近對NVAX發表了評論。摩根大通在週四的一份研究報告中將諾華的股票評級從中性下調至減持,並將該公司的目標價從132.00美元下調至27美元。考恩在8月15日星期一的一份研究報告中將諾華的目標價下調至110.00美元。B.萊利在7月22日星期五的一份研究報告中將諾華公司的目標價從181.00美元下調至171.00美元。考恩在8月9日週二的一份研究報告中將諾華鉑的目標價從150.00美元下調至110.00美元,並對該股設定了“跑贏大盤”的評級。最後,坎託·菲茨傑拉德在6月8日星期三的一份研究報告中將諾華公司的目標價從146.00美元上調至168.00美元。
Novavax Stock Performance
Novavax股票表現
NVAX opened at $21.00 on Thursday. The firm has a market cap of $1.64 billion, a P/E ratio of -1.08, a PEG ratio of 0.10 and a beta of 1.65. The firm has a 50-day moving average of $41.22 and a 200 day moving average of $52.06. Novavax has a fifty-two week low of $20.46 and a fifty-two week high of $257.30.
NVAX週四開盤報21.00美元。該公司的市值為16.4億美元,市盈率為-1.08,聚乙二醇率為0.10,貝塔係數為1.65。該公司的50日移動均線切入位在41.22美元,200日移動均線切入位在52.06美元。Novavax的52周低點為20.46美元,52周高位為257.30美元。
Institutional Inflows and Outflows
機構資金流入和流出
A number of institutional investors have recently bought and sold shares of NVAX. Mascoma Wealth Management LLC purchased a new position in Novavax during the 2nd quarter valued at approximately $27,000. San Luis Wealth Advisors LLC purchased a new position in Novavax during the 1st quarter worth approximately $29,000. Focused Wealth Management Inc purchased a new position in shares of Novavax during the 1st quarter valued at approximately $45,000. Exchange Traded Concepts LLC purchased a new position in shares of Novavax during the 2nd quarter valued at approximately $47,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Novavax in the 1st quarter worth $53,000. Institutional investors own 42.63% of the company's stock.
多家機構投資者最近買賣了NVAX的股票。Mascoma Wealth Management LLC在第二季度購買了Novavax的一個新頭寸,價值約為2.7萬美元。San Luis Wealth Advisors LLC在第一季度購買了Novavax的一個新頭寸,價值約2.9萬美元。Focus Wealth Management Inc.在第一季度購買了新的Novavax股票頭寸,價值約4.5萬美元。交易所交易的概念公司在第二季度購買了新的Novavax股票頭寸,價值約4.7萬美元。最後,Dixon Hughes Goodman Wealth Advisors LLC在第一季度購買了Novavax價值53,000美元的新股份。機構投資者持有該公司42.63%的股份。
Novavax Company Profile
Novavax公司簡介
(Get Rating)
(獲取評級)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Novavax,Inc.是一家生物技術公司,專注於疫苗的發現、開發和商業化,以預防嚴重的傳染病和滿足衞生需求。該公司的候選疫苗包括冠狀病毒候選疫苗NVX-CoV2373,它正在進行兩項第三階段試驗、一項IIb階段試驗和一項I/II階段試驗;NanoFlu,一種處於第三階段臨牀試驗的季節性四價流感疫苗候選產品;以及ResVax,一種呼吸道合胞病毒(RSV)融合(F)蛋白質納米顆粒疫苗候選產品。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- 免費獲取StockNews.com關於Novavax的研究報告(NVAX)
- 華爾街對Datadog的熱情會帶來巨大的收益嗎?
- MarketBeat:回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性?
- 好市多盈利後價格疲軟是買入的好時機嗎?
- 需要關注的2只半導體類股走勢逆轉
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
接受Novavax Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Novavax和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧